InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: None

Thursday, 03/23/2023 5:54:22 PM

Thursday, March 23, 2023 5:54:22 PM

Post# of 572
APTO Quarterly:

Reported a second response with TP53 patient (at 40mg)
Aptivate recruiting progressing rapidly; initiated the Tusp + Ven combo this week.
Activity with RAS mutated patients looks encouraging.
Thinking about Lux in B-cell and inflammation combinations.
Rice teased about big pharma interest in TUSP (stay tuned)
Significant data read-out in last quarter of 2023.
They will need some form of financing within the next six months (my opinion).

Summary: Science looks great, but bumpy road ahead.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News